CARD11-BCL10-MALT1 (CBM) signaling mediates TCR-induced NF-κB activation in Tregs and controls the conversion of resting Tregs to effector Tregs and disruption of the CBM complex is sufficient to prime the tumor environment for successful immune checkpoint therapy [41]. The gene discussed is NFKB1; the disease is neoplasm.